Lilly pill maintains weight loss after switching from injectables in trial [BNN Bloomberg (Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: BNN Bloomberg
An oral weight-loss pill would help Lilly further widen its lead over Novo Nordisk. Both Lilly and Novo are awaiting U.S. regulatory approvals for their pills, with a decision on Novo's oral Wegovy expected later this year and on Lilly's orforglipron early next year. In the late-stage trial, patients who took orforglipron for 52 weeks, after an initial treatment period of 72 weeks with Wegovy or Zepbound, showed superior weight maintenance compared to placebo, Lilly said. Patients who switched from Wegovy maintained their previously achieved weight loss with an average difference of 0.9 kilograms (kg), while those who switched from Zepbound maintained it with an average difference of five kg. The most commonly reported side effects were mild-to-moderate and gastrointestinal, consistent with previous studies on orforglipron. Lilly's pill helped patients lose 12.4 per cent of their body weight in a late-stage study. In a separate trial, Novo's pill led to a 16.6 per cent redu
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Fell Following a Profit Warning Release [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Submits New Drug Application to FDA for CagriSema Weekly Weight-Loss Injection [Yahoo! Finance]Yahoo! Finance
- Insulin Storage System Market Projected to Reach $617.40 Million by 2024 Amid Rising Diabetes Prevalence [Yahoo! Finance]Yahoo! Finance
- Fact-checking Trump: Economy, wages, immigration and more [MSNBC.com]MSNBC.com
- Novo Nordisk (NVO) Hit By Lowered Guidance [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website